Search results
Pacira Touts Positive Data From EXPAREL Study In Toe Correction Surgery
Benzinga via Yahoo Finance· 2 years agoPacira BioSciences Inc (NASDAQ: PCRX) announced topline results from its Phase 3 study of EXPAREL as...
Pacira's (PCRX) Label Expansion Study on Exparel Meets Goal
Zacks via Yahoo Finance· 2 years agoPacira's (PCRX) phase III study evaluating its marketed drug, Exparel, as a single-dose sciatic...
Pacira (PCRX) Gets FDA Nod for Exparel's Label Expansion
Zacks via Yahoo Finance· 6 months agoPacira BioSciences, Inc. PCRX announced that the FDA has approved its supplemental new drug...
Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong
Zacks via Yahoo Finance· 4 months agoPacira BioSciences, Inc. PCRX reported preliminary total revenues (unaudited) of $675.0 million for...
Pacira (PCRX) Q1 Earnings Miss Estimates, Revenues Beat
Zacks via Yahoo Finance· 1 year agoPacira BioSciences, Inc. PCRX reported first-quarter 2023 adjusted earnings of 53 cents per share,...
Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues
Zacks via Yahoo Finance· 2 months agoPacira BioSciences, Inc. PCRX reported fourth-quarter 2023 adjusted earnings of 89 cents per share,...
Pacira's (PCRX) sNDA for Exparel Accepted for FDA Review
Zacks via Yahoo Finance· 1 year agoThe FDA accepts Pacira's (PCRX) sNDA filing, which seeks to expand the label of its pain drug...
Q4 2023 Pacira Biosciences Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 2 months agoParticipants Anthony Molloy; Chief Legal & Compliance Officer; Pacira BioSciences, Inc. Anthony Malloy Charles A. Reinhart; CFO; Pacira BioSciences, Inc. Frank D. Lee; CEO & Director; Pacira ...
3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023
Zacks via Yahoo Finance· 1 year agoHere we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but...
Here's Why You Should Add Pacira (PCRX) Stock to Your Portfolio
Zacks via Yahoo Finance· 1 year agoPacira (PCRX) is witnessing strong growth on the back of its lead product, Exparel. Potential label...
